Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Leukemia, Myeloid, Acute 6Solid Tumor 2Myelodysplastic Syndromes 2Lymphoma, Non-Hodgkin 2Colorectal Neoplasms 2Urinary Bladder Neoplasms 1Unresectable Colorectal Cancer 1Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Recurrence 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Myeloid Malignancies 1Multiple Myeloma 1Lymphoma, Large B-Cell, Diffuse 1Hematologic Neoplasms 1Carcinoma, Transitional Cell 1

Interventions

magrolimab 1Oxaliplatin 1Nivolumab 1Leucovorin 1Fluorouracil 1Cetuximab 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Unresectable Colorectal Cancer × magrolimab × Clear all
NCT06540261 2024-09-19

The Study of ONO-7913, ONO-4538 and the Standard of Care as First-line Treatment in Patients Colorectal Cancer

Ono Pharmaceutical Co., Ltd.

Phase 1 Active not recruiting
65 enrolled
Gastrointestinal

Unresectable Colorectal Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡